Agenda
Applications for consideration at this meeting
- 1192.3 Reduction of mitral regurgitation through tissue approximation, using transvenous/transeptal techniques (Resubmission)
- 1344.2 Assessment of foot and ankle services by podiatric surgeons (resubmission)
- 1420.1 Extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma
- 1429.1 Targeted intraoperative radiotherapy for early-stage breast cancer
- 1466 Vertebroplasty for severely painful osteoporotic vertebral fractures of less than 6 weeks duration
- 1485.1 Sentinel Lymph Node Biopsy for intermediate thickness melanoma
- 1553 Transmural fixation of aortic endograft adjunct to endovascular aneurysm repair using helical anchors
- 1564 Review of immunoglobulin use for Chronic Inflammatory Demyelinating Polyneuropathy
- 1566 Review of immunoglobulin use for Myasthenia Gravis
- 1570 PD-L1 (Programmed Death Ligand 1) immunohistochemistry (IHC) testing for access to atezolizumab as first line therapy for patients with locally advanced or metastatic triple-negative breast cancer (TNBC)
- 1572 Diagnosis of hypertension using ambulatory blood pressure monitoring in patients with clinic blood pressure ≥ 140/90mmHg and ≤ 180/110mmHg
- 1607 17p deletion testing for access to acalabrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia
- 1621 Amendment to MBS Item 73344 for c-ROS proto-oncogene 1 fluorescence in situ hybridisation testing to identify ROS1, to determine patient eligibility for entrectinib under the Pharmaceutical Benefits Scheme
Related information
Committee: